U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C11H17NO3
Molecular Weight 211.2576
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISOPROTERENOL

SMILES

CC(C)NCC(O)C1=CC(O)=C(O)C=C1

InChI

InChIKey=JWZZKOKVBUJMES-UHFFFAOYSA-N
InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C11H17NO3
Molecular Weight 211.2576
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/cdi/isoproterenol.html | https://www.ncbi.nlm.nih.gov/pubmed/209581 | https://www.ncbi.nlm.nih.gov/pubmed/22073124 | https://www.ncbi.nlm.nih.gov/pubmed/11723224

Isoproterenol (trade names Medihaler-Iso and Isuprel) is a medication used for the treatment of bradycardia (slow heart rate), heart block, and rarely for asthma. Isoproterenol is a non-selective β adrenoreceptor agonist and TAAR1 agonist that is the isopropylaminomethyl analog of epinephrine. Isoprenaline's effects on the cardiovascular system (non-selective) relate to its actions on cardiac β1 receptors and β2 receptors on smooth muscle within the tunica media of arterioles. Isoprenaline has positive inotropic and chronotropic effects on the heart. β2 adrenoceptor stimulation in arteriolar smooth muscle induces vasodilation. Its inotropic and chronotropic effects elevate systolic blood pressure, while its vasodilatory effects tend to lower diastolic blood pressure. The overall effect is to decrease mean arterial pressure due to the β2 receptors' vasodilation. The adverse effects of isoprenaline are also related to the drug's cardiovascular effects. Isoprenaline can produce tachycardia (an elevated heart rate), which predisposes patients to cardiac arrhythmias.

Originator

Sources: Archiv fuer Experimentelle Pathologie und Pharmakologie, Volume 197, Pages 41-56, Journal, 1940

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

1956
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

1956
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

1956
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

1956
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
42 ng/mL
0.3 mg/kg single, subcutaneous
dose: 0.3 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
ISOPROTERENOL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg 1 times / day multiple, respiratory
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 27 - 67
Health Status: unhealthy
Age Group: 27 - 67
Sex: M+F
Sources:
Other AEs: Tachycardia, Premature ventricular contractions...
Other AEs:
Tachycardia (66.7%)
Premature ventricular contractions (8.3%)
Sources:
0.2 mg multiple, intravenous
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources:
unhealthy
Disc. AE: Block heart, Adams-Stokes syndrome...
AEs leading to
discontinuation/dose reduction:
Block heart
Adams-Stokes syndrome
Sources:
1 mg multiple, intramuscular
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources:
unhealthy
Disc. AE: Block heart, Adams-Stokes syndrome...
AEs leading to
discontinuation/dose reduction:
Block heart
Adams-Stokes syndrome
Sources:
AEs

AEs

AESignificanceDosePopulation
Tachycardia 66.7%
15 mg 1 times / day multiple, respiratory
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 27 - 67
Health Status: unhealthy
Age Group: 27 - 67
Sex: M+F
Sources:
Premature ventricular contractions 8.3%
15 mg 1 times / day multiple, respiratory
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 27 - 67
Health Status: unhealthy
Age Group: 27 - 67
Sex: M+F
Sources:
Adams-Stokes syndrome Disc. AE
0.2 mg multiple, intravenous
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources:
unhealthy
Block heart Disc. AE
0.2 mg multiple, intravenous
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources:
unhealthy
Adams-Stokes syndrome Disc. AE
1 mg multiple, intramuscular
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources:
unhealthy
Block heart Disc. AE
1 mg multiple, intramuscular
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Glucose uptake via SGLT-1 is stimulated by beta(2)-adrenoceptors in the ruminal epithelium of sheep.
2002-06
Vanillylamide-based propanolamine derivative displays alpha/beta-adrenoceptor blocking and vasodilating properties.
2002-06
Impaired intracellular signal transduction via cyclic AMP contributes to cerebral vasospasm in rats with subarachnoid hemorrhage.
2002-04
99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.
2002-02-21
Expression of human angiotensinogen-renin in rat: effects on transcription and heart function.
2002-02
The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation.
2002-02
Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats.
2002-02
Bone marrow-derived regenerated cardiomyocytes (CMG Cells) express functional adrenergic and muscarinic receptors.
2002-01-22
Decreased SOD activity and increased nitrates level in rat heart with left ventricular hypertrophy induced by isoproterenol.
2002-01-19
Synergistic effect of nicorandil and amlodipine on mitochondrial function during isoproterenol-induced myocardial infarction in rats.
2002-01
Allosteric modulation of beta2-adrenergic receptor by Zn(2+).
2002-01
Effects of alpha- and beta-adrenergic stimulation on free magnesium concentrations in platelets from healthy and obese individuals.
2001-12
Differential effects of atropine and isoproterenol on inducibility of atrioventricular nodal reentrant tachycardia.
2001-12
Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.
2001-12
In vitro activity of polyhydroxycarboxylates against herpesviruses and HIV.
2001-11
Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats.
2001-10
Activation of mitochondrial oxidative phosphorylation during (+/-)-isoproterenol-induced cell injury of myocardium.
2001-09-22
Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes.
2001-09-14
Report of a life-threatening arrhythmia after hospital discharge in a liver transplant recipient with previously unknown congenital long QT syndrome.
2001-09-01
A comparison of effects measured with isotonic and isometric recording: II. Concentration-effect curves for physiological antagonists.
2001-08
[Functional characterization of myocardial hypertrophy induced by isoproterenol and its regression].
2001-07
Different mechanisms of isoproterenol-induced and nitroglycerin-induced syncope during head-up tilt in patients with unexplained syncope: important role of epinephrine in nitroglycerin-induced syncope.
2001-07
A new aspect of view in synthesizing new type beta-adrenoceptor blockers with ancillary antioxidant activities.
2001-07
Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts.
2001-07
Alterative and plastic insufficiency of cardiomyocytes: isoproterenol-induced damage to myocardium during anthracycline cardiomyopathy.
2001-06
beta-Adrenergic and endothelin receptor interaction in dilated human cardiomyopathic myocardium.
2001-06
Cardioprotective effects of Picrorrhiza kurroa against isoproterenol-induced myocardial stress in rats.
2001-05
PKC-beta is not necessary for cardiac hypertrophy.
2001-05
Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system.
2001-04
Elevated parasympathetic nerve tone in isoproterenol-induced neurally mediated syncope during head-up tilt testing.
2001-04
Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo.
2001-03-13
Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal.
2001-03-02
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.
2001-03
Interaction of calcitonin gene-related peptide (CGRP), substance P (SP) and conventional autonomic agonists in rat submandibular salivary peroxidase release in vitro.
2001-01-14
Paroxysmal tachycardia in children and teenagers with normal sinus rhythm and without heart disease.
2001-01
Lipopolysaccharide-induced tumor necrosis factor-alpha release is controlled by the central nervous system.
2001
Recurrent asystoles associated with vasovagal reaction during venipuncture.
2000-12
[Effects of isoprenaline on apoptosis related gene expression in rat myocardium cells].
2000-11
Pharmacological effects of an aldehyde type alpha/beta-adrenoceptor blocking agent with vasodilating properties.
2000-06
[Pharmacology of acebutolol in animals].
1975-12-31
Serum prolactin levels in rats following isoproterenol-induced myocardial infarction.
1975-12
[Prevention of isoproterenol-induced lesions in the rat myocardium by prenylamine].
1975-09-01
Effects of prindolol on isoproterenol-induced subendocardial ischaemia in dogs with multiple chronic coronary artery occlusion.
1975-07
Metabolic responses following isoproterenol-induced myocardial infarction in arteriosclerotic breeder vs. non-arteriosclerotic virgin and ovariectomized female rats.
1975-05-01
The use of practolol in supraventricular arrhythmias associated with acute illnesses.
1975-05
Metabolic response after isoproterenol-induced myocardial infarction in arteriosclerotic breeder vs nonarteriosclerotic virgin intact and gonadectomized male rats.
1975-04
Prolyl hydroxylase and collagen metabolism after experimental mycardial infarction.
1975-01
[Myocardial DNA and cell count following isoproterenol-induced myocardial necrosis in the rat].
1975
Method for the production of severe ventricular dysrhythmias in small laboratory animals.
1975
Membrane phospholipid metabolism in the isoproterenol-induced cardiomyopathy of the rat.
1975
Patents

Sample Use Guides

Bolus intravenous injection: 0.02 mg to 0.06 mg; Intravenous infusion: 5 mcg/min; Intramuscular 0.2 mg; Subcutaneous 0.2 mg; Intracardiac 0.02 mg;
Route of Administration: Other
Human embryonic kidney cells (HEK293) were cultured in Minimum Essential Medium (MEM) Earle’s (Biochrom AG) supplemented with 10% FBS (PAA Laboratories GmbH), 100 U/ml penicillin, and 100 mg/ml streptomycin (Biochrom AG) and 2 mM L-glutamine (Invitrogen) at 37C with 5% CO2. 48 well plates were coated with Poly-L-Lysine (Biochrom) and HEK293 cells were seeded with 37,500 cells per well. Transient transfection in triplicates with 84 ng DNA/well using metafectene according to manufactures instructions (Biontex, Munich, Germany) was performed 28 hours later. 40 hours after transfection cells were pre-incubated for 5 minutes with stimulation buffer containing of MEM Earle’s media and 1 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma). This stimulation buffer was used for all further steps. For ligand competition experiments cells were incubated with tyramine, 2-phenylethylamine or octopamine ranging from 6.7 nM to 6700 nM, diluted in stimulation buffer for 15 minutes followed by a stimulation with isoprenaline in concentrations ranging from 1 nM to 10000 nM for 30 minutes. All reactions were performed at 37C with 5% CO2 saturated air and stopped by aspirating medium.
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:52:38 GMT 2025
Edited
by admin
on Wed Apr 02 07:52:38 GMT 2025
Record UNII
L628TT009W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Isoprenaline
INN   MART.   WHO-DD  
INN  
Preferred Name English
ISOPROTERENOL
MI   VANDF  
Common Name English
ALEUDRIN
Brand Name English
ASSIPRENOL
Brand Name English
ISOPROTERENOL [MI]
Common Name English
ISORENIN
Brand Name English
ISOPRENALINE [MART.]
Common Name English
ISONORIN
Brand Name English
NEO-EPININE
Brand Name English
ISOPROTERENOL DL-FORM [MI]
Common Name English
RESPIFRAL
Brand Name English
BELLASTHMAN
Brand Name English
ALUDRINE
Brand Name English
ISOPROTERENOL [VANDF]
Common Name English
NSC-9975
Code English
ASIPRENOL
Brand Name English
1,2-BENZENEDIOL, 4-(1-HYDROXY-2-((1-METHYLETHYL)AMINO)ETHYL)-
Systematic Name English
SAVENTRINE
Brand Name English
NOVODRIN
Brand Name English
3,4-DIHYDROXY-.ALPHA.-((ISOPROPYLAMINO)METHYL)BENZYL ALCOHOL
Systematic Name English
PROTERNOL
Brand Name English
Isoprenaline [WHO-DD]
Common Name English
ISOPROPYDRIN
Brand Name English
isoprenaline [INN]
Common Name English
ASMALAR
Brand Name English
VAPO-N-ISO
Brand Name English
NSC-33791
Code English
NEODRENAL
Brand Name English
ISUPREN
Brand Name English
A-21
Code English
Classification Tree Code System Code
WHO-VATC QC01CA02
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
NCI_THESAURUS C319
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
WHO-ATC C01CA02
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
WHO-ATC R03AK02
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
NDF-RT N0000175555
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
NDF-RT N0000000245
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
WHO-ATC R03CB01
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
WHO-ATC R03AB02
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
WHO-VATC QR03AB02
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
WHO-VATC QR03CB01
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
WHO-VATC QR03AK02
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
WHO-VATC QR03CB51
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
WHO-ATC R03CB51
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
Code System Code Type Description
SMS_ID
100000087152
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
ChEMBL
CHEMBL434
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
MESH
D007545
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
DRUG CENTRAL
1499
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
NSC
9975
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
WIKIPEDIA
ISOPRENALINE
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
CAS
7683-59-2
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
DRUG BANK
DB01064
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
CHEBI
64317
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
PUBCHEM
3779
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
MERCK INDEX
m6533
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY Merck Index
FDA UNII
L628TT009W
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
RXCUI
6054
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY RxNorm
IUPHAR
536
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
EVMPD
SUB08330MIG
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
EPA CompTox
DTXSID4023175
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
NSC
33791
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
MERCK INDEX
m6533
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY Merck Index
ECHA (EC/EINECS)
231-687-7
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
NCI_THESAURUS
C62041
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
INN
4201
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
DAILYMED
L628TT009W
Created by admin on Wed Apr 02 07:52:38 GMT 2025 , Edited by admin on Wed Apr 02 07:52:38 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
TARGET -> AGONIST
Assay in chinese hamster ovary (CHO) cells stably expressing the three ?-adrenergic receptor subtypes at comparable leve50 to 80 pM 125I-CYP were used as radioligand. Experiments were done in the presence of 100 µM GTP.
METABOLIC ENZYME -> SUBSTRATE
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC